Compare Huntington Bancshares Incorporated (HBAN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Tango Therapeutics Inc. — how do they compare? Huntington Bancshares Incorporated trades at $15.11 (market cap $30.79B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Huntington Bancshares Incorporated is far larger — about 8.2× Tango Therapeutics Inc.'s market cap, and Huntington Bancshares Incorporated pays a 4.07% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Tango Therapeutics Inc. for 0 Days on average.
| HBAN | TNGX | |
|---|---|---|
Market Cap | $30.79B | $3.75B |
Volume | 16,522,211 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $19.27 | $32.90 |
52-Week Low | $15.02 | $7.50 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | $49.31B | $2.77B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.10, down 1.95% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with a P/E of 11.72 and ROE of 9.23%, while revenue grew to $8.13B in 2025. Recent news highlights margin pressures from higher interest rates and a reduced 2027 outlook, though the company maintains shareholder returns through dividends and buybacks.
HBAN presents a cautious near-term outlook with analyst consensus at $19.60 (30% upside potential) but faces headwinds from net interest margin compression. Investment opportunity lies in valuation discount to peers, while risks include prolonged rate pressures and execution challenges in loan growth. The balanced analyst rating (47% Buy, 47% Hold) reflects uncertainty around timing of recovery.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
